These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. Rameis H Wien Med Wochenschr; 1993; 143(19-20):490-500. PubMed ID: 8135031 [TBL] [Abstract][Full Text] [Related]
4. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Murdoch D; Heel RC Drugs; 1991 Mar; 41(3):478-505. PubMed ID: 1711448 [TBL] [Abstract][Full Text] [Related]
5. The role of calcium antagonists in the treatment of myocardial ischemia. Follath F Am Heart J; 1989 Nov; 118(5 Pt 2):1093-6; discussion 1096-7. PubMed ID: 2683702 [TBL] [Abstract][Full Text] [Related]
6. Nilvadipine: profile of a new calcium antagonist. An overview. Rosenthal J J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101 [TBL] [Abstract][Full Text] [Related]
7. Amlodipine: a new calcium antagonist. Clavijo GA; de Clavijo IV; Weart CW Am J Hosp Pharm; 1994 Jan; 51(1):59-68. PubMed ID: 8135260 [TBL] [Abstract][Full Text] [Related]
8. Use of calcium channel antagonists for cardiovascular disease. Yedinak KC Am Pharm; 1993 Aug; NS33(8):49-64; quiz 64-6. PubMed ID: 8213473 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetic profile of amlodipine. Abernethy DR Am Heart J; 1989 Nov; 118(5 Pt 2):1100-3. PubMed ID: 2530866 [TBL] [Abstract][Full Text] [Related]
10. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Pearigen PD; Benowitz NL Drug Saf; 1991; 6(6):408-30. PubMed ID: 1793522 [TBL] [Abstract][Full Text] [Related]
13. [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect]. Heynen G Schweiz Rundsch Med Prax; 1992 Feb; 81(7):199-203. PubMed ID: 1531545 [TBL] [Abstract][Full Text] [Related]
14. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Herbette LG; Vecchiarelli M; Sartani A; Leonardi A Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437 [TBL] [Abstract][Full Text] [Related]
15. Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine. Opie LH Postgrad Med J; 1991; 67 Suppl 5():S2-8. PubMed ID: 1666430 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of vasodilators. Part I. Kirsten R; Nelson K; Kirsten D; Heintz B Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of calcium antagonists. An update. Kelly JG; O'Malley K Clin Pharmacokinet; 1992 Jun; 22(6):416-33. PubMed ID: 1587055 [TBL] [Abstract][Full Text] [Related]
19. Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Friedel HA; Sorkin EM Drugs; 1988 Dec; 36(6):682-731. PubMed ID: 3065058 [TBL] [Abstract][Full Text] [Related]
20. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Brogden RN; Markham A Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]